Talima Therapeutics, a Santa Clara, Calif., developer of techniques that limit drug delivery to specific parts of the body, raised $19 million in a second funding round. The company’s release is here.
The company is at work on localized drug-delivery techniques that could serve as alternatives to systemic drugs, potentially improving their effectiveness while limiting side effects. Its initial focus lies in dermatology, a field in which “local application” — that is, ointments, creams and lotions — is already in common practice. Talima hasn’t revealed much about its technology beyond describing it as a “micro-implant” system, which could mean almost anything. The new funding will carry its leading drug candidates — whatever they are — into mid-stage human testing.
The round was led by US Venture Partners and Latterell Venture Partners, joined by current investors De Novo Ventures and Palo Alto Healthcare.
VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.
